{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:34:04Z","timestamp":1787045644300,"version":"build-2736575974"},"reference-count":63,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Objectives: The aim of this study was to determine whether direct evidence shows that contemporary guideline-directed heart failure (HF) pharmacotherapies influence cardiac remodeling through hydrogen sulfide (H2S) signaling, and to define the resulting evidence gap. Design: A systematic review was conducted according to PRISMA 2020. Registration: PROSPERO CRD420251238589. Data Sources: MEDLINE (PubMed), Web of Science, Scopus, and the Cochrane Library; searches were initiated in March 2025, covered publications from January 2007 onward, and were last updated in November 2025. Eligibility Criteria: Primary studies had to include (A) an HF or cardiac-remodeling model, (B) an HF-relevant pharmacological intervention, (C) direct assessment or manipulation of H2S biology, and (D) at least one cardiac-remodeling endpoint. Results: Of the 40,796 unique records screened, 50 reports underwent full-text assessment and 14 unique studies were included. No study demonstrated that the remodeling benefits of ACE inhibitors, ARBs, ARNIs, beta-blockers, MRAs, hydralazine\/isosorbide dinitrate, or SGLT2 inhibitors are mediated by endogenous H2S signaling. Doiron et al. evaluated empagliflozin with or without the H2S donor SG1002 in experimental HFpEF; the combination improved several outcomes beyond empagliflozin alone, but this adjunctive design does not establish H2S mediation of empagliflozin action. Most eligible evidence concerned exogenous H2S donors in animal models and reported improvements in fibrosis, hypertrophy, oxidative stress, mitochondrial injury, and cardiac function. The overall certainty was low because of preclinical predominance, heterogeneous models and H2S assays, donor-specific pharmacology, and incompletely reported randomization and blinding. Conclusions: The principal finding is negative but clinically important: direct evidence that H2S mediates established HF pharmacotherapy is currently absent. H2S remains a promising experimental therapeutic candidate rather than an established shared mechanism or clinically validated treatment target.<\/jats:p>","DOI":"10.3390\/diseases14080299","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:06:41Z","timestamp":1787044001000},"page":"299","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Effects of Heart Failure Medications on Cardiac Remodeling via the Hydrogen Sulfide (H2S) Pathway: A Systematic Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2172-0432","authenticated-orcid":false,"given":"Mohamed Thabit","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Omdurman Islamic University, Khartoum 14415, Sudan"},{"name":"Department of Pharmacology, Faculty of Pharmacy, Ege University, Izmir 35100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7832-4556","authenticated-orcid":false,"given":"Bashir A.","family":"Yousef","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology, Ibn Sina National College of Medical Studies, Jeddah 22421, Saudi Arabia"},{"name":"Department of Pharmacology, Faculty of Pharmacy, University of Khartoum, Khartoum 11111, Sudan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonen","family":"Ozsarlak-Sozer","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Ege University, Izmir 35100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahir","family":"Yagdi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Faculty of Medicine, Ege University, Izmir 35100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanem","family":"Nalbantgil","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Faculty of Medicine, Ege University, Izmir 35100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine Nur","family":"Ozbek","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Pharmacy, Ege University, Izmir 35100, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmoiz","family":"Babekir","sequence":"additional","affiliation":[{"name":"Department of Medicine and Adult Critical Care Medicine, Ibn Sina College for Medical Studies, Jeddah 22421, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2627-7115","authenticated-orcid":false,"given":"Khalid A.","family":"Ateyyah","sequence":"additional","affiliation":[{"name":"College of Medicine, Taibah University, Madinah 42353, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4277-6856","authenticated-orcid":false,"given":"Mohammed Ahmed","family":"Zahrani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1574-7871","authenticated-orcid":false,"given":"Sultan","family":"Almuallem","sequence":"additional","affiliation":[{"name":"Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3468-2903","authenticated-orcid":false,"given":"Alaa","family":"Mousli","sequence":"additional","affiliation":[{"name":"Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2033-1723","authenticated-orcid":false,"given":"Mohammed","family":"Basendowah","sequence":"additional","affiliation":[{"name":"Department of Surgery, Faculty of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1152\/physrev.1999.79.1.215","article-title":"Molecular mechanisms of myocardial remodeling","volume":"79","author":"Swynghedauw","year":"1999","journal-title":"Physiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jcmg.2010.10.008","article-title":"Left ventricular remodeling in heart failure: Current concepts in clinical significance and assessment","volume":"4","author":"Konstam","year":"2011","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.cardfail.2012.04.011","article-title":"Total plasma sulfide in congestive heart failure","volume":"18","author":"Glavnik","year":"2012","journal-title":"J. Card. Fail."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"15560","DOI":"10.1073\/pnas.0705891104","article-title":"Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function","volume":"104","author":"Elrod","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"691070","DOI":"10.1155\/2015\/691070","article-title":"Hydrogen sulfide donor GYY4137 protects against myocardial fibrosis","volume":"2015","author":"Meng","year":"2015","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.redox.2017.11.020","article-title":"Novel H2S-NO hybrid molecule (ZYZ-803) promoted synergistic effects against heart failure","volume":"15","author":"Wu","year":"2018","journal-title":"Redox Biol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Huang, C., Kan, J., Liu, X., Ma, F., Tran, B.H., Zou, Y., Wang, S., and Zhu, Y.Z. (2013). Cardioprotective effects of a novel hydrogen sulfide agent-controlled release formulation of S-propargyl-cysteine on heart failure rats and molecular mechanisms. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0069205"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Ahmad, A., Sattar, M.A., Rathore, H.A., Abdullah, N.A., Khan, S.A., Abdulla, M.H., and Johns, E.J. (2016). Up-regulation of cystathionine gamma-lyase and hydrogen sulphide in the myocardium inhibits the progression of isoproterenol-caffeine induced left ventricular hypertrophy in Wistar Kyoto rats. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150137"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41420-017-0010-9","article-title":"Glucose-6-phosphate dehydrogenase is critical for suppression of cardiac hypertrophy by H2S","volume":"4","author":"Chhabra","year":"2018","journal-title":"Cell Death Discov."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11010-013-1686-7","article-title":"Exogenous hydrogen sulfide prevents cardiomyocyte apoptosis from cardiac hypertrophy induced by isoproterenol","volume":"381","author":"Lu","year":"2013","journal-title":"Mol. Cell. Biochem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_17","first-page":"e41","article-title":"2025 Heart Disease and Stroke Statistics: A report of US and global data from the American Heart Association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/CIRCULATIONAHA.113.001878","article-title":"Pathological ventricular remodeling: Mechanisms: Part 1 of 2","volume":"128","author":"Burchfield","year":"2013","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/01.CIR.81.4.1161","article-title":"Ventricular remodeling after myocardial infarction: Experimental observations and clinical implications","volume":"81","author":"Pfeffer","year":"1990","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: A comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1146\/annurev-pharmtox-010510-100505","article-title":"Hydrogen sulfide and cell signaling","volume":"51","author":"Li","year":"2011","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1161\/CIRCHEARTFAILURE.113.000299","article-title":"Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis","volume":"6","author":"Polhemus","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1161\/CIRCRESAHA.118.311134","article-title":"Evolution of hydrogen sulfide therapeutics to treat cardiovascular disease","volume":"123","author":"Li","year":"2018","journal-title":"Circ. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Hooijmans, C.R., Rovers, M.M., de Vries, R.B.M., Leenaars, M., Ritskes-Hoitinga, M., and Langendam, M.W. (2014). SYRCLE\u2019s risk of bias tool for animal studies. BMC Med. Res. Methodol., 14.","DOI":"10.1186\/1471-2288-14-43"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/bph.12825","article-title":"Exogenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates angiotensin II-induced hypertensive heart disease in rats","volume":"172","author":"Snijder","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jacbts.2018.08.011","article-title":"Hydrogen sulfide attenuates renin angiotensin and aldosterone pathological signaling to preserve kidney function and improve exercise tolerance in heart failure","volume":"3","author":"Li","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"22344","DOI":"10.18632\/oncotarget.15765","article-title":"Protective effect of hydrogen sulphide against myocardial hypertrophy in mice","volume":"8","author":"Shao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1111\/bph.16493","article-title":"Adjunctive therapy with an oral H2S donor provides additional therapeutic benefit beyond SGLT2 inhibition in cardiometabolic heart failure with preserved ejection fraction","volume":"181","author":"Doiron","year":"2024","journal-title":"Br. J. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3892\/br.2013.87","article-title":"Hydrogen sulfide upregulates heme oxygenase-1 expression in rats with volume overload-induced heart failure","volume":"1","author":"Zhang","year":"2013","journal-title":"Biomed. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2119\/molmed.2013.00096","article-title":"Hydrogen sulfide alleviates myocardial collagen remodeling in association with inhibition of TGF-beta\/Smad signaling pathway in spontaneously hypertensive rats","volume":"20","author":"Sun","year":"2015","journal-title":"Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3892\/mmr.2012.748","article-title":"Hydrogen sulfide attenuates cardiac hypertrophy and fibrosis induced by abdominal aortic coarctation in rats","volume":"5","author":"Huang","year":"2012","journal-title":"Mol. Med. Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1161\/CIRCULATIONAHA.112.000855","article-title":"H2S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase","volume":"127","author":"Kondo","year":"2013","journal-title":"Circulation"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3892\/mmr.2016.5289","article-title":"Hydrogen sulfide exhibits cardioprotective effects by decreasing endoplasmic reticulum stress in a diabetic cardiomyopathy rat model","volume":"14","author":"Li","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"95425","DOI":"10.18632\/oncotarget.20729","article-title":"Gas signaling molecule hydrogen sulfide attenuates doxorubicin-induced dilated cardiomyopathy","volume":"8","author":"Yu","year":"2017","journal-title":"Oncotarget"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/cvr\/cvaa123","article-title":"Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase G\u03b1 oxidation","volume":"117","author":"Kolijn","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e003531","DOI":"10.1161\/JAHA.116.003531","article-title":"Zofenopril protects against myocardial ischemia-reperfusion injury by increasing nitric oxide and hydrogen sulfide bioavailability","volume":"5","author":"Donnarumma","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ejvs.2021.09.032","article-title":"Hydrogen sulphide release via the angiotensin converting enzyme inhibitor zofenopril prevents intimal hyperplasia in human vein segments and in a mouse model of carotid artery stenosis","volume":"63","author":"Macabrey","year":"2022","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"479","DOI":"10.33549\/physiolres.932772","article-title":"Captopril partially decreases the effect of H2S on rat blood pressure and inhibits H2S-induced nitric oxide release from S-nitrosoglutathione","volume":"64","author":"Drobna","year":"2015","journal-title":"Physiol. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3409\/fb59_3-4.151-155","article-title":"Carvedilol induces endogenous hydrogen sulfide tissue concentration changes in various mouse organs","volume":"59","author":"Wilinski","year":"2011","journal-title":"Folia Biol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1113\/JP285720","article-title":"Metabolomics of repetitive myocardial stunning in chronic multivessel coronary artery stenosis: Effect of non-selective and selective \u03b21-receptor blockers","volume":"602","author":"Le","year":"2024","journal-title":"J. Physiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"104281","DOI":"10.1016\/j.phrs.2019.104281","article-title":"Histone deacetylase 6 inhibitor tubastatin A attenuates angiotensin II-induced hypertension by preventing cystathionine \u03b3-lyase protein degradation","volume":"146","author":"Chi","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hu, H.J., Wang, X.H., Liu, Y., Zhang, T.Q., Chen, Z.R., Zhang, C., Tang, Z.-H., Qu, S.-L., Tang, H.-F., and Jiang, Z.-S. (2021). Hydrogen sulfide ameliorates angiotensin II-induced atrial fibrosis progression to atrial fibrillation through inhibition of the Warburg effect and endoplasmic reticulum stress. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.690371"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1093\/cvr\/cvu026","article-title":"Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition","volume":"102","author":"Bucci","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Tesch, G.H., and Young, M.J. (2017). Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00313"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.cellsig.2013.07.010","article-title":"Dysregulation of cystathionine \u03b3-lyase (CSE)\/hydrogen sulfide pathway contributes to ox-LDL-induced inflammation in macrophage","volume":"25","author":"Wang","year":"2013","journal-title":"Cell. Signal."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1046\/j.1440-1681.2003.03906.x","article-title":"Spironolactone prevents cardiac collagen proliferation after myocardial infarction in rats","volume":"30","author":"Mill","year":"2003","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/hr.2014.125","article-title":"Hydrogen sulfide treatment reduces blood pressure and oxidative stress in angiotensin II-induced hypertensive mice","volume":"38","author":"Hart","year":"2015","journal-title":"Hypertens. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/1755-5922.12128","article-title":"A novel hydrogen sulfide prodrug, SG1002, promotes hydrogen sulfide and nitric oxide bioavailability in heart failure patients","volume":"33","author":"Polhemus","year":"2015","journal-title":"Cardiovasc. Ther."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"102474","DOI":"10.1016\/j.redox.2022.102474","article-title":"Mitochondrial oxidative stress contributes to diastolic dysfunction through impaired mitochondrial dynamics","volume":"57","author":"Lozhkin","year":"2022","journal-title":"Redox Biol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.bbrc.2019.05.021","article-title":"Angiotensin II downregulates vascular endothelial cell hydrogen sulfide production by enhancing cystathionine \u03b3-lyase degradation through ROS-activated ubiquitination pathway","volume":"514","author":"Bai","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"965","DOI":"10.7150\/ijms.93720","article-title":"The crucial relationship between miRNA-27 and CSE\/H2S, and the mechanism of action of GLP-1 in myocardial hypertrophy","volume":"21","author":"Gao","year":"2024","journal-title":"Int. J. Med. Sci."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"12560","DOI":"10.3390\/ijms160612560","article-title":"Homocysteine triggers inflammatory responses in macrophages through inhibiting CSE-H2S signaling via DNA hypermethylation of CSE promoter","volume":"16","author":"Li","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Munteanu, C., Rotariu, M., Turnea, M., Dogaru, G., Popescu, C., Spinu, A., Andone, I., Postoiu, R., Ionescu, E.V., and Oprea, C. (2022). Recent advances in molecular research on hydrogen sulfide (H2S) role in diabetes mellitus (DM)\u2014A systematic review. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23126720"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Zhang, L., Wang, Y., Li, Y., Li, L., Xu, S., Feng, X., and Liu, S. (2018). Hydrogen sulfide (H2S)-releasing compounds: Therapeutic potential in cardiovascular diseases. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.01066"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"MERIT-HF Study Group (1999). Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet, 353, 2001\u20132007.","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1001\/jama.289.6.712","article-title":"for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of initiating carvedilol in patients with severe chronic heart failure: Results from the COPERNICUS study","volume":"289","author":"Krum","year":"2003","journal-title":"JAMA"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Ananda, R.A., Mori, T.A., and Yang, J. (2025). Aldosterone and cardiovascular risk across the lifespan. Metabolites, 15.","DOI":"10.3390\/metabo15080553"}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/8\/299\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T09:22:34Z","timestamp":1787044954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/14\/8\/299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":63,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["diseases14080299"],"URL":"https:\/\/doi.org\/10.3390\/diseases14080299","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]}}}